Arcus Biosciences, Inc. reported impairment of long-lived assets for the first quarter ended March 31, 2024. For the quarter, the company reported impairment of long-lived assets of $20 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.07 USD | +0.94% | -6.51% | -21.10% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.10% | 1.37B | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- RCUS Stock
- News Arcus Biosciences, Inc.
- Arcus Biosciences, Inc. Reports Impairment of Long-Lived Assets for the First Quarter Ended March 31, 2024